nChroma Bio
Latest round
- Series I
Last raised
- Dec 2024
Total raised
- $75M
Investors
- 19
About nChroma Bio
Founded in 2024 and based in the US, nChroma Bio, formed as a merger between Chroma Medicine and Nvelop Therapeutics, operates as a biotechnology research company that develops genetic medicines using epigenetic editing and in vivo delivery technologies. nChroma Bio is a biotechnology company focused on developing in vivo targeted genetic medicine. Its approach addresses limitations in existing genetic therapies by ensuring safe and precise gene delivery. The company's key development candidate, CRMA-1001, is a liver-targeted treatment for chronic hepatitis B and D, utilizing epigenetics to regulate gene expression. The therapy aims to provide a functional cure for these conditions. nChroma Bio is advancing innovative treatments with a focus on durable, targeted gene regulation, with potential applications extending beyond liver-related diseases.
Who invested in nChroma Bio
19 investors across 1 round
See all investors in nChroma Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series I
Dec 11, 2024
Amount
$75M
Investors
Questions about nChroma Bio
Who invested in nChroma Bio?
nChroma Bio has 19 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has nChroma Bio raised?
nChroma Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did nChroma Bio last raise money?
nChroma Bio's most recent round on record is a Series I, in Dec 2024.
What does nChroma Bio do?
Founded in 2024 and based in the US, nChroma Bio, formed as a merger between Chroma Medicine and Nvelop Therapeutics, operates as a biotechnology research company that develops genetic medicines using epigenetic editing and in vivo delivery technologies.
Where is nChroma Bio headquartered?
nChroma Bio is headquartered in Boston, US.
Which VCs invest in companies like nChroma Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at nChroma Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series I
Raising like nChroma Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.